Mineralys Therapeutics Inc MLYS

$23.63 -0.09 (-0.38%)

Valuation

Market cap
2,097,014,000
Revenue TTM
$0
Net income TTM
$-154,650,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.18

Trading

Volume
928,200
Avg volume
1,095,836
Day's range
$23.55 – $24.34
Shares out
88,407,000
Stochastic %K
1%
Beta
0.69
Analysts
Strong Sell
Price target
$48.50

Price

Company profile

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep a...

Show more

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
888 378 6240
Website
https://mineralystx.com
Address
150 N. Radnor Chester Road, Suite F200, Radnor, United States

Latest news

Stocktwits

CH_Expat Oct 2, 4:50 PM
$MLYS I can only imagine being a rookie and having bought after the data in the high 40s and now holding bags and watch the bleeding here. As I am a contrarian investor, I am not concerned at all. The XBI YTD underperformance is now 65%. The same XBI that is full of shitcos and retail lotto players while we have 120% institutional ownership. In my opinion, if you have no position and think about deploying cash in a non-shit-bio, this is the best opportunity in all of bio right now. No investment advice.
1 replies
OnlyBioLover Oct 1, 8:49 PM
$MLYS back in. stock is basically half its 52w high and the risk is lower now, not higher. phase 3 done, nda accepted, fda date dec 22. az got the same type of drug approved in may so the fda already said yes to the mechanism once. ~560m net cash, ev around 1.6b. yeah az is the competition, and a big early holder keeps selling down, i get it. but that's supply, not a problem with the drug, and 14% of the float is short into a pdufa. i'll take that setup at 23,8. aha nov 8 next.
1 replies
CH_Expat Oct 1, 3:26 PM
$MLYS Different ticker, same conclusion.
4 replies
Valueforall Oct 1, 12:56 AM
$GLUE $MLYS $VERA Props 🙌👌 to this fellow for always knowing where to be in the land of broken obscurity That is some kinda talent.
0 replies
CH_Expat Sep 30, 1:11 PM
$MLYS I am not Felix Baker, but I have been there.SWTX, CRNX, BPMC. This posting was made when SWTX hit 27. BO was low eventually, but the thesis was right.
3 replies
CH_Expat Sep 29, 4:23 PM
$MLYS Okay, realtalk here: You will not find any other stock with that high institutional ownership and a conservative peak sale potential of at least 1b (very conservative) trading that bad YTD in XBI. Bax is killing it on the launch and there is an argument Loru has a better profile in various ways. So why did we underperform XBI by 60%? YTD I do find an answer apart from manipulation as I found no answers at IDYA, SWTX, CRNX. So I bought a lot and I am ready to buy more as long as it looks like algo and MM games. At the moment, it does to me.
3 replies
CH_Expat Sep 29, 3:27 PM
$MLYS Just the beginning.
1 replies
Jakeipedia Sep 29, 2:34 PM
$MLYS ah wtf another 200 shares for me
0 replies